Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CCL2 | P13500 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777608 | 0.83 | HTR2A (0.38) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL31131312 | 0.80 | HTR2A (0.35) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL2902860 | 0.80 | HTR2A (0.39) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL22932183 | 0.80 | BRD4 (0.36) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL2322179 | 0.80 | HTR2A (0.35) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL30232400 | 0.80 | HTR2A (0.39) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL14393119 | 0.72 | HTR2A (0.35) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL24654162 | 0.68 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL275865 | 0.67 | HTR2A (0.41) | HTR2AHTR6BRD4CCL2CYP2D6 | |
| SCHEMBL194747 | 0.67 | HTR2A (0.38) | HTR2AHTR6BRD4CCL2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HTR2A 4611/4885HTR6 3104/4885BRD4 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.